Company intelligence / Profile preview

Tarsier Pharma

Ownership: Private
Development stage: Phase 3

Overview

Tarsier’s lead candidate, TRS01 (Dazdotuftide), has shown positive results in the TRS4Vision trial. The company received FDA Special Protocol Assessment agreement for its pivotal Phase 3 trial (Tarsier-04) evaluating TRS01 eye drops for non-infectious uveitis and uveitic glaucoma. The protocol was designed to replicate prior successful trials with revised endpoints to emphasize benefit/risk profile. Preparations are underway to enroll up to 300 patients in the US; the company believes it will meet primary endpoints based on previous strong results[6].

Therapeutic areas: Ophthalmology
Modalities: Small molecules (notably Dazdotuftide/TRS01)[1][3]
Industry: Biotech

Drug pipeline

2 assets

dazdotuftide

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tarsier Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarsier Pharma.

Explore the full profile